Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
HaploSCT in Older Patients with AML Evaluated
Biol Blood Marrow Transplant; ePub 2017 Sep 13; Ciurea, et al
Haploidentical transplantation (haploSCT) was found to be safe and effective for older patients with acute myeloid leukemia or myelodysplastic syndrome. Participants were a median 61 years of age and underwent a haploSCT at a single institution. All received reduced-intensity conditioning and post-transplant GVHD prophylaxis. Among the results:
1 patient died early, but the remainder engrafted donor cells.
At 6 months, cumulative incidence of grade 2-4 acute GVHD was 35%; it was 5% for grade 3-4 acute GVHD.
Chronic GVHD at 2 years was 9%.
2-year overall and progression-free survival rates were each 42%; relapse incidence was 24%.
Patients with intermediate/good-risk cytogenetics, in first or second remission, or who had a donor ≤40 years of age had the best progression-free survival rate (74%).
Ciurea S, Shah M, Saliba R, et al. Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome. [Published online ahead of print September 13, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.09.005.
This Week's Must Reads
Must Reads in AML
Immune system changes play a role in AML relapse, Christopher MJ et al. N Engl J Med. 2018 Oct 31. doi: 10.1056/NEJMoa1808777.
Venetoclax plus HMA studied in AML, DiNardo C et al. Blood. 2018 Oct 25. doi: 10.1182/blood-2018-08-868752.
T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51
Higher AML, MDS risk linked to autotransplants, Radivoyevitch T et al. Leuk Res. 2018 Jul 19. pii: S0145-2126(18)30160-7
Tibsovo for AML with IDH1 mutation, FDA approves first targeted treatment for patients with relapsed or refractory acute myeloid leukemia who have a certain genetic mutation, FDA press release
